ACL 8.33% 1.3¢ alchemia limited

Cash is king

  1. 1,052 Posts.
    lightbulb Created with Sketch. 1
    At one time we said punting on Alchemia was a better bet than going to the track. It turns out you would probably have had a better time at Flemington.

    The stock fell 80 per cent in one day in October after the company announced its big hope, the HA-Irinotecan cancer treatment, failed to meet targets. But one factor that drew us to Alchemia was its worth wasn’t simply based on research and development.

    A recent announcement by the company indicates it is far from a lost cause, as it prepares to return to investors the more than $10m a year in revenue from fondaparinux, its generic treatment for deep vein thrombosis.

    Similarly, when we first looked at Medical Developments, we were impressed by its historic strong annual operating cashflow of between $2m and $4m.

    Medical technology companies are no different from other investments — cash today talks louder than potential tomorrow.


    http://m.theaustralian.com.au/busin...210987833?nk=9d04e0f453e1cc48a9dc8b81c8077fd8
 
watchlist Created with Sketch. Add ACL (ASX) to my watchlist
(20min delay)
Last
1.3¢
Change
0.00(8.33%)
Mkt cap $3.896M
Open High Low Value Volume
1.2¢ 1.5¢ 1.2¢ $160.8K 12.15M

Buyers (Bids)

No. Vol. Price($)
1 85042 1.3¢
 

Sellers (Offers)

Price($) Vol. No.
1.4¢ 840000 5
Last update - 16.10pm 23/10/2018 (20 minute delay) ?
(live)
Last
1.3¢
  Change
0.00 ( 8.33 %)
Open High   Low Volume
1.2¢ 1.4¢   1.2¢ 7394231
Last updated 15.37pm 23/10/2018 (live) ?
ACL (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.